...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Ophthalmology >Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients
【24h】

Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients

机译：贝伐单抗（Avastin）治疗中的安全性监测：通过心理生理学（视野，色觉）和电生理学（ERG / EOG）测试评估了两个亚组患者的视网膜功能

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Bevacizumab (Avastin™) has been used as off-label treatment for the specific inhibition of the vascular endothelial growth factor (VEGF). Although only intravenous administration of the drug is approved in combination therapy of colorectal carcinoma, promising short-term results have been reported about its intravitreal administration. However, VEGF is also known to exhibit neurotrophic capabilities. Therefore, blockage of all VEGF isoforms by bevacizumab could induce toxic effects. Missing randomized controlled studies and unclear long-term risks require further evaluation.
机译：背景技术贝伐单抗（Avastin™）已被用作非标记治疗，用于特异性抑制血管内皮生长因子（VEGF）。尽管在大肠癌的联合治疗中仅批准该药物的静脉内给药，但有关玻璃体内给药的短期结果已有报道。然而，还已知VEGF表现出神经营养能力。因此，贝伐单抗阻断所有VEGF同工型均可能引起毒性作用。缺少随机对照研究和不清楚的长期风险需要进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号